Triple oral therapy for type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 78, Issue 3, 2007, Pages 313-315

  Bell, David S H ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C REACTIVE PROTEIN; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL;

EID: 35648970583     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.01.003     Document Type: Note

References (22)

1. Dailey III G.E. Early insulin: an important therapeutic strategy. Diabetes Care 28 1 (2005) 220-221
2. Roberts V.L., Stewart J., Issa M., Lake B., and Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. 27 10 (2005 Oct) 1535-1547
3. Bell D.S. Insulin as initial therapy for type 2 diabetes is not in the patient's best interest. Endocr. Pract. 10 3 (2004 May-Jun) 208-212
4. Yale J.F., Valiquett T.R., Ghazzi M.N., Owens-Grillo J.K., Whitcomb R.W., and Foyt H.L. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 134 9 Pt 1 (2001) 737-745
5. Ovalle F., and Bell D.S. Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocr. Pract. 4 3 (1998) 146-147
6. Gavin L.A., Barth J., Arnold D., and Shaw R. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control. Endocr. Pract. 6 4 (2000) 305-310
7. Hershon K.S., and Hershon P.M. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice. Endocr. Pract. 6 1 (2000) 20-25
8. Dailey III G.E., Noor M.A., Park J.S., Bruce S., and Fiedorek F.T. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am. J. Med. 116 4 (2004) 223-229
9. Rosenstock J., Sugimoto D., Strange P., Stewart J.A., Soltes-Rak E., and Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29 3 (2006) 554-559
10. Reynolds, Diabetes Research and Clinical Practice, 2007.
11. Bell D.S., and Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr. Pract. 8 4 (2002) 271-275
12. Bell D.S., and Ovalle F. Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes. Diabetes Obes. Metab. 8 1 (2006) 110-115
13. Ovalle F., and Bell D.S. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care 27 11 (2004) 2585-2589
14. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators:
15. Gerstein H.C., Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N., Hanefeld M., Hoogwerf B., Laakso M., Mohan V., Shaw J., Zinman B., and Holman R.R. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 9541 (2006) 1096-1105
16. Kahn S.E., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355 23 (2006) 2427-2443
17. Bell D.S. A comparison of agents used to manage type 2 diabetes mellitus: need for reappraisal of traditional approaches. Treat Endocrinol. 3 2 (2004) 67-76
18. Mazzone T., Meyer P.M., Feinstein S.B., Davidson M.H., Kondos G.T., D'Agostino Sr. R.B., Perez A., Provost J.C., and Haffner S.M. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296 21 (2006 Dec 6) 2572-2581
19. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R.J., Koranyi L., Laakso M., Mokan M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Skrha J., Smith U., and Taton J. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 9493 (2005) 1279-1289
20. Dandona P., Mohanty P., Chaudhuri A., Garg R., and Aljada A. Insulin infusion in acute illness. J. Clin. Invest. 115 8 (2005) 2069-2072
21. Panahloo A., Mohamed-Ali V., Andres C., Denver A.E., and Yudkin J.S. Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes. Metabolism 47 6 (1998) 637-643
22. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., Tan M.H., Khan M.A., Perez A.T., and Jacober S.J. GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 7 (2005) 1547-1554